Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Apr 12;43(1):9-12.
doi: 10.1093/pubmed/fdaa181.

Clinical impact of COVID-19 on people with substance use disorders

G Vallecillo  1   2 , R Perelló  3 , R Güerri  2   4 , F Fonseca  1   2 , M Torrens  1   2
Affiliations
Observational Study

Clinical impact of COVID-19 on people with substance use disorders

G Vallecillo et al. J Public Health (Oxf). .

Abstract

Background: People with substance use disorders are considered at increased risk of COVID-19 and its more serious complications, however data on the impact of COVID-19 are lacking. The study aimed to describe the clinical characteristics and outcomes of COVID-19 on people with substance use disorders.

Methods: an observational study was carried out including patients aged ≥ years with COVID-19 pneumonia admitted to an urban hospital during March 12 to June 21,2020.

Results: Among 2078 patients admitted, 27 (1.3%) were people with substance use disorders: 23(85.2%) were men with a median age of 56.1 + 10.3 years and. The main SUD were alcohol in 18(66.7%) patients, heroine in 6(22.2%) and cocaine in 3(11.1%) and 24(88.8%) patients were on ongoing substance use disorder treatment. One or more comorbidities associated to COVID-19 risk were observed in 18(66.6%) of patients. During a median length of stay of 10 days (IQR:7-19), severe pneumonia developed in 7(25.9%) patients, acute respiratory distress syndrome in 5 (18.5%) and none died.

Conclusion: Larger sample sizes and sero-epidemiological studies are needed to confirm the low incidence of severe COVID-19 on patients with SUD.

Keywords: COVID-19; drugs; substance use disorders.

PubMed Disclaimer

References

    1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72?314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020;323(13):1239–42. - PubMed
    1. Yang J, Zheng Y, Gou X et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis 2020;94:91–5. - PMC - PubMed
    1. Severe outcomes among patients with coronavirus disease 2019 (COVID-19) — United States, February 12–march 16, 2020. MMWR Morb Mortal Wkly Rep 2020;69:343–6. - PMC - PubMed
    1. Garg S, Kim L, Whitaker M et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 - COVID-NET, 14 states, March 1-30, 2020. MMWR Morb Mortal Wkly Rep 2020;69(15):458–64. - PMC - PubMed
    1. Berenguer J, Ryan P, Rodríguez-Baño J et al. Characteristics and predictors of death among 4,035 consecutively hospitalized patients with COVID-19 in Spain. Clin Microbiol Infect 2020. S1198-743X(20)30431-6. - PMC - PubMed

Publication types